Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SC CLS-TA
CLS-TA · 2 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| 4 mg CLS-TA + IVT aflibercept | EXPERIMENTAL | Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept |
| sham + IVT aflibercept | ACTIVE_COMPARATOR | Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept |
| 4 mg CLS-TA | EXPERIMENTAL | Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA |
| 0.8 mg CLS-TA | EXPERIMENTAL | Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA |
| Name | Type | Description |
|---|---|---|
| 4 mg CLS-TA | DRUG | 40 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension) |
| Sham | DRUG | suprachoroidal sham procedure |
| IVT aflibercept | DRUG | 2 mg intravitreal injection of aflibercept |
| 0.8 mg CLS-TA | DRUG | 8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension) |
Inclusion Criteria: * diagnosis of macular edema following RVO * History of ME ≤ 12 months * 20-70 letters inclusive BCVA using ETDRS Exclusion Criteria: * has had an IVT injection of anti-VEGF for RVO in the study eye * has had a corticosteroid injection in the past 3 months in the study eye * a...
Top 16 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| 4D Molecular Therapeutics, Inc. | FDMT | 2 | PHASE3 | 4D-150, EYELEA |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE3 | Aflibercept |
| Hoffmann-La Roche | RHHBY | 6 | PHASE3 | Ranibizumab, Susvimo, RO7497372, RO7823653, Faricimab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | MK-8748 |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | Surabgene Lomparvovec |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tabirafusp tedromer |
| Alvotech | ALVO | 1 | PHASE3 | AVT29 |
| Kiora Pharmaceuticals, Inc. | KPRX | 1 | PHASE2 | KIO-104 |
| REGENXBIO, Inc. | RGNX | 1 | PHASE2 | RGX-314 |
| BioAge Labs, Inc. | BIOA | 1 | PHASE2 | BGE-102 |
| Ocugen Inc | OCGN | 1 | PHASE1 | OCU200 |
| Surrozen Inc | SRZN | 1 | PHASE1 | SZN-8141 |
| Adverum Biotechnologies, Inc. | ADVM | 1 | - | ADVM-022 |
| Bayer | BAYRY | 1 | - | Aflibercept |
CLS-TA is an investigational small molecule therapy being developed by Clearside Biomedical, Inc. for ophthalmic conditions. It is a formulation of triamcinolone acetonide designed for suprachoroidal injection, a targeted delivery approach to the back of the eye. It is in Phase 2 clinical development for macular edema associated with uveitis and retinal vein occlusion.
CLS-TA is being studied for the treatment of macular edema, including macular edema following retinal vein occlusion and macular edema associated with non-infectious uveitis. These are inflammatory and vascular conditions of the eye that cause fluid accumulation in the macula. CLS-TA remains investigational and has not been approved for commercial use.
CLS-TA is being developed by Clearside Biomedical, Inc., which trades under the ticker CLSD. The company is advancing the candidate as a suprachoroidally administered therapy for macular edema associated with retinal vein occlusion and non-infectious uveitis.
CLS-TA is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 2 program includes completed trials in macular edema following retinal vein occlusion and in macular edema associated with non-infectious uveitis.
CLS-TA has been evaluated in two completed Phase 2 trials. NCT02303184 studied suprachoroidal injection of triamcinolone acetonide with intravitreal aflibercept in 46 subjects with macular edema following retinal vein occlusion. NCT02255032 studied suprachoroidal triamcinolone acetonide in 22 subjects with macular edema following non-infectious uveitis.